NovoCure Limited
novocure.comWhat Do They Do?
Sells wearable medical devices that deliver electric-field therapy to adult cancer patients, including those with brain, lung and pancreatic tumors.
10-K for FY2025, filed Feb 26, 2026We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric…View ↗
Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of…View ↗
Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic NSCLC concurrent with…View ↗
Optune Pax is approved by the FDA under the PMA pathway for the treatment of adult patients with locally advanced pancreatic cancer…View ↗
TTFields therapy is delivered through a portable medical device. The complete device, called Optune Gio (for the treatment of GBM), Optune…View ↗
Who Are Their Customers?
Patients use the devices under a prescription and patient service agreement; Novocure seeks payment from public and private payers, and seeks reimbursement case by case for Optune Lua and Optune Pax where coverage policies are being pursued.
10-K for FY2025, filed Feb 26, 2026We have established coverage policies with both public and private payers for the use of Optune Gio in our active markets. We are actively…View ↗
1.Identify the contract with a patient. A contract with a patient exists when (i) the Company enters into an enforceable contract with a…View ↗
Our revenues are primarily derived from patients using our Products in our active markets. We charge for treatment with our Products on a…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 23, 2026
−$15.7MView ↗
- ▼ −61% (Loss)
- vs −$40.1M in Q2 FY2025
-
Jul 23, 2026
Raised full-year revenue and adjusted EBITDA guidance
Full-year revenue guidance rose to $710 million-$725 million from $690 million-$710 million; adjusted EBITDA guidance rose to $0 million-$15 million from $(15) million-$0 million.
Sources
8-K, filed Jul 23, 2026
Total net revenue: $710 million - $725 million (previous: $690 million - $710 million) Guidance includes collective net revenue…View ↗
-
Jun 30, 2026
Optune Pax received CE Mark for pancreatic cancer in Europe
The CE Mark covers treatment of locally advanced pancreatic cancer with gemcitabine and nab-paclitaxel, subject to local guideline recommendations.
Sources
8-K, filed Jun 30, 2026
On June 30, 2026, the Company issued a press release announcing that that that Optune Pax® has received a CE (Conformité Européenne) Mark…View ↗
Broader treatment portfolio
The older report described Optune for glioblastoma and Optune Lua for mesothelioma; the latest report describes Optune Gio for glioblastoma, Optune Lua for lung cancer and mesothelioma, and Optune Pax for pancreatic cancer.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric…View ↗
Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of…View ↗
Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic NSCLC concurrent with…View ↗
Optune Pax is approved by the FDA under the PMA pathway for the treatment of adult patients with locally advanced pancreatic cancer…View ↗
Loading...
